Last reviewed · How we verify
Autologous cell therapy
Autologous cell therapy involves harvesting a patient's own cells, processing or expanding them ex vivo, and reinfusing them to restore function or modulate immune responses.
At a glance
| Generic name | Autologous cell therapy |
|---|---|
| Sponsor | Dr. Grant M. Pagdin |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Immunology |
| Phase | Phase 3 |
Mechanism of action
The therapy isolates cells from the patient's own body, which are then cultured, expanded, or genetically modified outside the body to enhance their therapeutic properties. These cells are subsequently reintroduced into the patient to repair damaged tissues, replace lost cell populations, or enhance immune function. This approach leverages the patient's own cellular machinery to achieve therapeutic benefit while minimizing rejection risk.
Approved indications
Common side effects
- Infusion-related reactions
- Cytokine release syndrome
- Infection
- Graft-versus-host disease (if allogeneic)
Key clinical trials
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |